Zhao Dongming, Fukuyama Satoshi, Sakai-Tagawa Yuko, Takashita Emi, Shoemaker Jason E, Kawaoka Yoshihiro
Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo, Japan ERATO Infection-Induced Host Responses Project, Japan Science and Technology Agency, Saitama, Japan.
Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo, Japan.
Antimicrob Agents Chemother. 2015 Dec 28;60(3):1902-6. doi: 10.1128/AAC.02055-15.
New strategies to develop novel broad-spectrum antiviral drugs against influenza virus infections are needed due to the emergence of antigenic variants and drug-resistant viruses. Here, we evaluated C646, a novel p300/CREB-binding protein-specific inhibitor of histone acetyltransferase (HAT), as an anti-influenza virus agent in vitro and in vivo and explored how C646 affects the viral life cycle and host response. Our studies highlight the value of targeting HAT activity for anti-influenza drug development.
由于抗原变异体和耐药病毒的出现,需要开发针对流感病毒感染的新型广谱抗病毒药物的新策略。在此,我们评估了C646,一种新型的组蛋白乙酰转移酶(HAT)的p300/CREB结合蛋白特异性抑制剂,作为一种体外和体内抗流感病毒药物,并探讨了C646如何影响病毒生命周期和宿主反应。我们的研究突出了靶向HAT活性在抗流感药物开发中的价值。